Litcius/Paper detail

Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms

Peng-Chong Zhu, Jiayi Shen, Ren-Yi Qian, Jian Xu, Chong Liu, Wu‐Ming Hu, Ying Zhang, Ling-Chun Lv

2023Frontiers in Pharmacology20 citationsDOIOpen Access PDF

Abstract

Introduction: Tanshinone IIA (Tan IIA), the major active lipophilic ingredient of Radix Salviae Miltiorrhizae , exerts various therapeutic effects on the cardiovascular system. We aimed to identify the preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent in the treatment of myocardial ischemia/reperfusion injury. Methods: The study quality scores of twenty-eight eligible studies and data analyses were separately assessed using the CAMARADES 10-item checklist and Rev-Man 5.3 software. Results: The study quality score ranged from 3/10 to 7/10 points. The present study provided preliminary preclinical evidence that Tan IIA could significantly decrease the myocardial infarct size, cardiac enzyme activity and troponin levels compared with those in the control group ( p < 0.05 ). Discussion: Tan IIA alleviated myocardial I/R injury via antioxidant, anti-inflammatory, anti-apoptosis mechanisms and improved circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent for the treatment of myocardial ischemia/reperfusion injury and should be further investigated in clinical trials.

Topics & Concepts

MedicinePharmacologyIschemiaReperfusion injuryMyocardial ischemiaMyocardial infarctionCardioprotectionAntioxidantCardiologyInternal medicineBiochemistryChemistryTraditional Chinese Medicine AnalysisCardiac Ischemia and ReperfusionMetabolomics and Mass Spectrometry Studies
Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms | Litcius